[Intravitreal ranibizumab for age-related macular degeneration].
BACKGROUND
Ranibizumab has improved visual prognosis for patients with age-related macula degeneration (ARMD) complicated with choroidal neovascularisation. We evaluated the results of all our patients within a two-year period.


METHODS
A total of 647 eyes have so far been treated. In all 2,735 injections have been performed.


RESULTS
Ranibizumab initially increased significantly the best corrected visual acuity from 0.29 to 0.35 (p < 0.001), but after six and 12 months visual acuity stabilized (p = 0.1). We found a positive correlation between initial visual acuity and final visual acuity (p < 0.001). There was a negative correlation between age and final visual acuity (p < 0.001). Complications were rare: one got cataract, we observed a retinal detachment and one choroidal detachment. Other complications were rare and mild.


CONCLUSIONS
Ranibizumab improves visual prognosis in exudative ARMD. Intravitreal injections are safe and complications are rare.
Øjenafdelingen, Sygehus Nord, Roskilde, 4000 Roskilde, Denmark. torbenls@dadlnet.dk
Torben Lykke
TL
Sørensen
Henrik
H
Kemp
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D011379:Prognosis; D000069579:Ranibizumab; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab